Post-marketing Surveillance (PMS) of all Patients Treated with Irinotecan in Japan: Clinical Experience and ADR Profile of 13 935 Patients

Abstract

It was reconfirmed that the incidences of serious leukopenia, thrombocytopenia and diarrhea were high among the patients with contraindication or careful administration of its use prescribed in the drug package insert. Therefore, for proper use of irinotecan, it is important to discriminate the patient on the basis of risk status.